Finally, only a minor part of the study population in the present study was treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i), which were shown to decrease the risk of cardiovascular mortality and HF-related rehospitalization in HFmrEF [32]. This evidence concerns the gene SLC5A2 and hydrops fetalis.